Nicox (LTS:0RCQ) FFO


LTS:0RCQ Nicox SA LTS:0RCQ
40 GF Score
Price €0.36
GF Value €0.69
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nicox FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0RCQ
40GF Score
Nicox SA LTS:0RCQ
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nicox (LTS:0RCQ) Overvalued in 2026?

Based on GuruFocus' analysis, Nicox stock appears to be undervalued. The current stock price of €0.36 is trading 47.6% below its estimated GF Value™ of €0.69. GuruFocus considers Nicox to be Possible Value Trap.

Key valuation signals for LTS:0RCQ:

  • FFO:
  • GF Value™: €0.69 vs. price of €0.36 (47.6% below fair value)
  • GF Score™: 40/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RCQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nicox Business Description

Other Exchanges ALCOX:FranceNXOA:Germany
Address Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
40GF Score

Get the complete analysis for LTS:0RCQ

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.36
Price
€0.69
GF Value